FDA grants accelerated approval to Nova Therapeutics gene therapy for spinal muscular atrophy
rulingbreakingverified
✓ Verified Facts
FDA issued accelerated approval for NVT-401, a one-time gene therapy for Type 2 SMA
Source: FDA Press Release NR-2026-0211
95%
Phase 3 trial showed 73% of patients achieving independent sitting at 18 months
Source: New England Journal of Medicine, published Feb 8 2026
92%
Treatment is priced at $2.1 million per patient
Source: Nova Therapeutics investor presentation, Feb 9 2026
90%
💬 Attributed Claims
Dr. Voss stated the therapy "represents a paradigm shift in rare disease treatment"
Source: Dr. Elena Voss, Nova Therapeutics press conference
85%
⚠ Not Yet Confirmed
Insurance coverage decisions pending from major carriers
Long-term efficacy data beyond 24 months not yet available